Psychiatric Genetic Epidemiology & Neurobiology Laboratory, Medical Genetics Research Center, Department of Psychiatry and Behavioral Sciences & Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, New York 13210, USA.
Am J Med Genet B Neuropsychiatr Genet. 2011 Dec;156B(8):869-87. doi: 10.1002/ajmg.b.31239. Epub 2011 Oct 3.
Several studies have evaluated the potential utility of blood-based whole-transcriptome signatures as a source of biomarkers for schizophrenia. This endeavor has been complicated by the fact that individuals with schizophrenia typically differ from appropriate comparison subjects on more than just the presence of the disorder; for example, individuals with schizophrenia typically receive antipsychotic medications, and have been dealing with the sequelae of this chronic illness for years. The inability to control such factors introduces a considerable degree of uncertainty in the results to date. To overcome this, we performed a blood-based gene-expression profiling study of schizophrenia patients (n = 9) as well as their unmedicated, nonpsychotic, biological siblings (n = 9) and unaffected comparison subjects (n = 12). The unaffected biological siblings, who may harbor some of the genetic predisposition to schizophrenia, exhibited a host of gene-expression differences from unaffected comparison subjects, many of which were shared by their schizophrenic siblings, perhaps indicative of underlying risk factors for the disorder. Several genes that were dysregulated in both individuals with schizophrenia and their siblings related to nucleosome and histone structure and function, suggesting a potential epigenetic mechanism underlying the risk state for the disorder. Nonpsychotic siblings also displayed some differences from comparison subjects that were not found in their affected siblings, suggesting that the dysregulation of some genes in peripheral blood may be indicative of underlying protective factors. This study, while exploratory, illustrated the potential utility and increased informativeness of including unaffected first-degree relatives in research in pursuit of peripheral biomarkers for schizophrenia.
已有多项研究评估了基于血液的全转录组特征作为精神分裂症生物标志物的潜在效用。但由于精神分裂症患者与合适的对照人群之间的差异并不仅仅在于疾病的存在,这使得这一努力变得复杂。例如,精神分裂症患者通常会接受抗精神病药物治疗,并且多年来一直受这种慢性疾病的影响。无法控制这些因素给迄今为止的研究结果带来了相当大的不确定性。为了克服这一困难,我们对 9 名精神分裂症患者(病例组)及其未经药物治疗、非精神病性的生物学兄弟姐妹(对照组)和 12 名无相关疾病的对照受试者进行了基于血液的基因表达谱研究。未受影响的生物学兄弟姐妹可能携带部分精神分裂症的遗传易感性,与无相关疾病的对照受试者相比,他们表现出许多基因表达差异,其中许多与他们的精神分裂症兄弟姐妹共享,这可能表明存在该疾病的潜在风险因素。在精神分裂症患者及其兄弟姐妹中存在一些失调的基因与核小体和组蛋白结构和功能有关,这表明该疾病的风险状态可能存在潜在的表观遗传机制。非精神病性的兄弟姐妹与对照组之间也存在一些差异,而这些差异在他们受影响的兄弟姐妹中没有发现,这表明一些基因在外周血中的失调可能是潜在保护因素的指标。虽然这项研究是探索性的,但它说明了在研究中纳入未受影响的一级亲属以寻找精神分裂症的外周生物标志物的潜在效用和增加信息量。